Table 1 Baseline characteristics of enrolled patients and group comparison according to the type of ULD used
Whole sample (n = 245) | Allopurinol (n = 208) | Febuxostat (n = 35) | P | |
|---|---|---|---|---|
Age (years), mean (SD) | 63.5 (13.5) | 62.1 (13.2) | 72.2 (11.8) | < 0.001 |
Male | 212 (86.5) | 189 (90.9) | 22 (62.9) | < 0.001 |
HT | 169 (69.0) | 137 (65.9) | 30 (85.7) | 0.019 |
DM | 60 (24.5) | 47 (22.6) | 13 (37.1) | 0.065 |
DL | 128 (52.2) | 107 (51.4) | 20 (57.1) | 0.532 |
Smoking background (n = 234) | 140 (59.9) | 128 (64.3) | 12 (36.4) | 0.006 |
CVD | 61 (24.9) | 45 (21.6) | 16 (45.7) | 0.002 |
Diuretic therapy | 109 (44.5) | 86 (41.3) | 23 (65.7) | 0.007 |
Type of diuretics (n = 243) | 0.005 | |||
Thiazides | 61 (25.1) | 51 (24.5) | 10 (28.6) | |
Loop agents | 46 (18.9) | 33 (15.9) | 13 (37.1) | |
Combination of diuretics | 11 (4.5) | 7 (3.4) | 4 (11.4) | 0.057 |
BMI (kg/m2), mean (SD) | 29.9 (5.2) | 30.0 (5.0) | 30.2 (6.0) | 0.790 |
eGFR (mL/min), mean (SD) (n = 243) | 71.5 (26.4) | 76.6 (23.4) | 40.8 (23.0) | < 0.001 |
Chronic kidney disease (n = 241) | 76 (31.5) | 47 (22.8) | 29 (82.9) | < 0.001 |
SU (mg/dL), mean (SD) | 8.3 (1.7) | 8.2 (1.4) | 9.3 (2.4) | 0.008 |
Prior use of ULD (n = 243) | 58 (23.9) | 50 (24.1) | 8 (22.9) | 0.914 |